15353-j-veluchamy

140 | Chapter 5 Supplementary figure 2: Schedule of in vivo BRGS wt mouse experiments. BRGS wt mice were divided in 4 groups of 6 mice each. SW480 (A) is the control group, followed by treatment groups SW480 + cetuximab (B), SW480 + UCB-NK (C) and SW480 + UCB-NK + cetuximab (D). 0.5 x 106 Gluc transduced SW480 cells per mouse were administered i.v. to all groups at day 0. On day 1 (dose I) post tumor injection, Groups B and D mice were treated with 0.5mg cetuximab i.p. and Groups C and D were infused i.v. with 10 x 106 UCB-NK cells. Same doses of cetuximab and UCB-NK cells were again administered on day 4 (dose II) and day 7 (dose III) to the respective groups. 0.5µg IL-15 was mixed with 7.5 µg IL-15Rα and administered to the UCB-NK-treated groups on days 1, 4, 7, 10 and 14. Treatment effects were monitored using blood Gluc levels and BLI imaging studies, 10µl of blood was withdrawn twice a week and tumors were imaged 4 weeks after end of treatment.